Universitätsklinikum Düsseldorf
Location
Hagen | Germany
Job description
The Department of Pediatric Oncology, Hematology and Clinical Immunology at the University Hospital Düsseldorf (UKD) at the Heinrich Heine University (HHU), headed by Prof. Dr. Arndt Borkhardt, is one of the largest clinical centers for the diagnosis and treatment of childhood cancer in Germany.
The clinic is part of the University Tumor Center (UTZ) at the UKD and the Center for Integrative Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO-ABCD), which is funded by the German Cancer Aid. It is a founding partner of the German Consortium for Translational Cancer Research (DKTK) Essen-Düsseldorf and participates in international research consortia and study groups. The clinic operates a fully equipped research laboratory (safety level 1/2 according to the Genetic Engineering/Biotechnology Ordinance, including a GMP, next generation sequencing, flow cytometry, life cell imaging, and high-throughput drug testing facility) with 5 research groups and >30 staff working in an interdisciplinary manner on the fundamentals of childhood cancer and in the field of therapy optimization.
At the Department of Pediatric Oncology, Hematology and Clinical Immunology, a full-time position is available as soon as possible for an initial period of three years with the option of extension. The position will be remunerated according to group 13 TV-L.
We are aiming to enhance our in-house sequencing facility and are seeking postdoctoral scientists with relevant experience particularly in the principles of next generation sequencing techniques (Illumina, PacBio, ONT), to join our interdisciplinary research team of biologists, medical doctors and bioinformaticians.
Our clinic is conducting prospective, ongoing studies (see: Comprehensive germline-genomic and clinical profiling in 160 unselected children and adolescents with cancer. Wagener R, et al. Eur J Hum Genet. 2021 Aug;29(8):1301-1311 and Optical Genome Mapping Identifies Novel Recurrent Structural Alterations in Childhood ETV6::RUNX1+ and High Hyperdiploid Acute Lymphoblastic Leukemia. Brandes D, et al. Hemasphere. 2023 Jul;7(8):e925) to investigate cancer predisposition syndromes using SNP array, trio-whole exome/genome (NextSeq550, Illumina) or long read whole genome (Sequel II, PacBio) sequencing and whole genome mapping (Saphyr, Bionano Genomics) of affected children and their parents (“germline study”). The goals of our studies is to gain new insights into childhood carcinogenesis, to identify and functionally characterize novel cancer predisposition syndromes, and to use the data to develop new bioinformatics algorithms in Big Data Science.
Job tags
Salary
